Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – June 2019
Sarcoidosis is an inflammatory disease of unclear etiology. It is characterized by tissue infiltration of granulomas, most commonly into the lung and lymph nodes, but the skin, heart, eyes, liver, and other tissues may also be affected. Although many sarcoidosis patients have nonprogressive disease or experience remission without treatment, more-severe disease can lead to organ damage (e.g., lung fibrosis) and necessitate pharmacotherapy, often with oral glucocorticoids. Although a modest evidence base drives use of conventional oral immunosuppressants and TNF-alpha inhibitors in the management of sarcoidosis, approved treatment options are greatly needed for patients who do not respond to, or are poor candidates for, oral corticosteroids.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
John Crowley, , is an analyst in the CNS disorders group at Decision Resources. Prior to joining the company, Dr. Crowley was a postdoctoral associate at Harvard Medical School, where he studied mechanisms regulating the strength and dynamics of synaptic connections. He earned a from the University of Massachusetts Medical School, where he conducted research on the modulation of ion channel function by membrane lipids, and a from Worcester Polytechnic Institute.